Karyopharm Therapeutics Inc
KPTI5.410USD
-0.320-5.58%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
46.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Karyopharm Therapeutics Inc Unternehmen
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Unternehmensinformationen
BörsenkürzelKPTI
Name des UnternehmensKaryopharm Therapeutics Inc
IPO-datumNov 06, 2013
CEOMr. Richard A. Paulson
Anzahl der mitarbeiter279
WertpapierartOrdinary Share
GeschäftsjahresendeNov 06
Addresse85 Wells Avenue
StadtNEWTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02459
Telefon16176580600
Websitehttps://karyopharm.com/
BörsenkürzelKPTI
IPO-datumNov 06, 2013
CEOMr. Richard A. Paulson
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Andere
72.51%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
Andere
72.51%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
20.86%
Hedge Fund
16.35%
Research Firm
7.96%
Corporation
5.28%
Investment Advisor/Hedge Fund
4.11%
Venture Capital
1.83%
Individual Investor
1.14%
Bank and Trust
0.03%
Andere
42.45%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
BofA Global Research (US)
132.91K
1.54%
+122.13K
+1132.80%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Datum
Art
Verhältnis
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
